At the 2016 World Congress on Osteoarthritis (OARSI) meeting last week, first line results of a novel intraarticular inhibitor of the Wnt pathway (SM04690) in knee osteoarthritis were presented. 

Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).

On February 9th, the Food and Drug Administration (FDA) Arthritis Advisory Committee voted 21-3 in favor of approving the infliximab biosimilar, CT-P13/Inflectra, for use in all of infliximab's indications.

Researchers at Brigham and Women's Hospital, Boston evaluated the efficacy and safety of the anti-inflammatory drug losmapimod on cardiovascular outcomes given to patients with a history of myocardial infarction and CV risk factors.

The American College of Cardiology has released its expert consensus guidance regarding the use of non-statin therapies to lower cholesterol in high-risk patients.

Knee effusions in osteoarthritis are estimated to occur in 44% of patients, and more than half of these are painful.  Management of knee OA with effusions can be problematic given the treatment options and the high recurrence rate.

Highlights from this week on RheumNow.com

Opioid use and abuse is at an all time high. Epidemiologic and public health analyses have led to greater stringency and attempts to limit use have adversely effected those with arthritis.

The small molecule oral JAK inhibitor baricitinib was effective for patients with highly refractory rheumatoid arthritis, a phase III study found.

(Reuters Health) - Twelve weeks of antibiotic therapy proved ineffective at combating the long-term symptoms seen in some people who have had Lyme disease, a new test of 280 sufferers found. (Citation source http://buff.ly/1Rs21R5)

Eating a Mediterranean diet full of fruits, vegetables, fish, nuts, legumes and whole grains appears to be associated with a lower risk of hip fracture in women, although the actual risk reduction was small, according to a new study published online by JAMA Internal Medicine.

1. phase 3, BRIDGE study shows romosozumab (anti-sclerostin MAb) significantly increases lumbar BMD in men with osteoporosis


2. Statin use is associated with a 21% increased risk of skin cancer (NMSC) - data

A three-therapy protocol did not prove superior for achieving remission in rheumatoid arthritis (RA) patients after 1 year, but the regimen did lead to a shorter time until first remission versus a step-up approach, according to an analysis of the DREAM registry.

Qato and colleagues have published in JAMA a cohort study that examined the use of both prescription and over-the-counter medications among older adults and the frequency of major drug-drug interactions. The study shows the elderly are especially at risk, and the situation is

Comparative efficacy trials may be the best way to make informed treatment choices in a sea of treatment options for rheumatoid arthritis (RA).  Recent years have seen impressive head-to-head (H2H) clinical trials for RA, including AMPLE (abatacept vs.

Tuesday the FDA approved the IL-17 inhibitor, Taltz (ixekizumab) for adults with moderate to severe plaque psoriasis. (Citation source http://buff.ly/1py10wd) 

See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them. 

In the current issue of JBMR, Kim and colleagues from Brigham and Women's Hospital in Boston assessed US claims data and studied the impact of three FDA drug safety warnings regarding the use of bisphosphonates.

A network analysis of multiple therapies used in osteoarthritis found that acetaminophen (paracetamol) does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.

In February 2016, RheumNow published 82 tweets about impactful news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 80,800 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.